Heron TherapeuticsHRTX
HRTX
About: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Employees: 122
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2,362% more call options, than puts
Call options by funds: $4.21M | Put options by funds: $171K
56% more capital invested
Capital invested by funds: $176M [Q4 2024] → $274M (+$98.6M) [Q1 2025]
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
6.31% more ownership
Funds ownership: 75.57% [Q4 2024] → 81.88% (+6.31%) [Q1 2025]
2% more funds holding
Funds holding: 161 [Q4 2024] → 164 (+3) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
107%
upside
Avg. target
$5
159%
upside
High target
$6
211%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Brandon Folkes | 211%upside $6 | Buy Initiated | 9 Jun 2025 |
Needham Serge Belanger | 107%upside $4 | Buy Reiterated | 11 Apr 2025 |
Financial journalist opinion
Positive
Seeking Alpha
1 month ago
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025
HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-year adjusted EBITDA guidance, but potential equity offerings to manage debt remain a risk. HRTX's CEO speaks of Zynrelef's multi-hundred-million-dollar potential, although it may take several more quarters of sales growth to convince the market of that potential.
Neutral
Seeking Alpha
1 month ago
Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Conference Call Participants Yuxi Dong - Jefferies Serge Belanger - Needham & Company Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call.
Neutral
Zacks Investment Research
1 month ago
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
1 month ago
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates
Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.
Neutral
PRNewsWire
1 month ago
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI ® and APONVIE ® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025 CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates.
Neutral
PRNewsWire
1 month ago
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI® (aprepitant) injectable emulsion and APONVIE® (aprepitant) injectable emulsion.
Positive
Zacks Investment Research
1 month ago
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
1 month ago
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
CARY, N.C. , April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry.
Positive
Zacks Investment Research
1 month ago
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Positive
Zacks Investment Research
1 month ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Charts implemented using Lightweight Charts™